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with matched sibling or
unrelated donor HCT in
DLBCL.
• Three-year OS and
PFS after haplo-HCT
was 46% and 38%,
respectively, in DLBCL.
This study retrospectively compared long-term outcomes of nonmyeloablative/reduced
intensity conditioning (NMC/RIC) allogeneic hematopoietic cell transplantation (allo-HCT)
from a haploidentical family donor (haplo-HCT) using posttransplant cyclophosphamide
(PTCy) with those of matched sibling donor (MSD) andmatched unrelated donor (MUD) with
or without T-cell depletion (TCD1/TCD2) in patients with relapsed diffuse large B-cell
lymphoma (DLBCL). Adult patients with DLBCL who had undergone their ﬁrst NMC/RIC
allo-HCT between 2008 and 2015 were included. Recipients of haplo-HCT were limited to
those receiving graft-versus-host disease (GVHD) prophylaxis with PTCy. GVHD prophylaxis
in MSD was limited to calcineurin inhibitor (CNI)–based approaches without in vivo TCD,
while MUD recipients received CNI-based prophylaxis with or without TCD. Outcome
analyses for overall survival (OS) and progression-free survival (PFS), nonrelapse
mortality (NRM), and disease relapse/progression were calculated. A total of 1438 patients
(haplo, 132; MSD, 525; MUD TCD1, 403; and MUD TCD2, 378) were included. Patients with
haplo donors were signiﬁcantly older, had a better performance status and had more
frequently received total body irradiation-based conditioning regimens and bone marrow
grafts than MSD and MUD TCD1 or TCD2. 3-year OS, PFS, NRM and relapse/progression
incidence after haplo-HCT was 46%, 38%, 22%, and 41%, respectively, and not significantly
different from outcomes of matched donor transplants on multivariate analyses.
Haplo-HCT was associated with a lower cumulative incidence of chronic GVHD
compared with MSD, MUD TCD1/TCD2. NMC/RIC haplo-HCT with PTCy seems to be a
valuable alternative for patients with DLBCL considered for allo-HCT but lacking a
matched donor.
Submitted 26 October 2018; accepted 2 January 2019. DOI 10.1182/
bloodadvances.2018027748.
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The full-text version of this article contains a data supplement.
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Introduction
Although rituximab-based chemoimmunotherapy (CIT) is highly
effective in diffuse large B-cell lymphoma (DLBCL), 20% to 40%
of patients with DLBCL do not respond to standard first-line CIT
or experience disease recurrence within 1 year after diagnosis.
Only a minority of these early failures can be durably rescued
by high-dose chemotherapy with autologous hematopoietic cell
transplantation (auto-HCT), while the majority will be chemother-
apy resistant.1,2 Although chimeric antigen receptor–engineered
T cells (CAR-T cells) have been recently approved for patients with
DLBCL who have failed second-line CIT,3,4 an accepted alternative
salvage strategy in this poor-risk setting in eligible patients is
cellular immunotherapy by allogeneic hematopoietic cell trans-
plantation (allo-HCT).5-7 Using well-matched sibling donors (MSDs)
or unrelated donors (MUDs), allo-HCT can result in sustained
disease control in 30% to 45% of patients with DLBCL who
have early disease recurrence after standard CIT or have failed
auto-HCT.8-12 However, the search for a well-matched unrelated
donor could be time-consuming and unsuccessful in up to 50% of
the patients in need.13
With the introduction of posttransplant cyclophosphamide-based
immunosuppression (PTCy), allo-HCT using haploidentical related
donors (haplo-HCT) has emerged as a valuable alternative for
patients without an available MSD or MUD.14-16 Similar to other
allo-HCT standard indications, PTCy haplo-HCT seems to provide
disease control and survival rates comparable to MSD/MUD
transplants (using conventional calcineurin inhibitor [CNI]–based
prophylaxis) in patients with lymphoma despite a significantly reduced
risk of chronic graft-versus-host disease (GVHD) compared with the
traditional donor sources.14,17-22 However, these results derive from
retrospective analyses of patient samples with the global diagnoses
of Hodgkin lymphoma and/or non-Hodgkin lymphoma (NHL). Since in
particular the various NHL subsets are characterized by fundamen-
tal differences in biology and allo-HCT efficacy,23 disease-specific
studies on the main NHL entities are mandatory. Here, we provide




The study was performed through collaboration between the
European Society for Blood and Marrow Transplantation (EBMT)
and the Center for International Blood and Marrow Transplant
Research (CIBMTR) lymphoma working committees. EBMT is a
voluntary organization comprising 640 transplant centers mainly
from Europe. Accreditation as a member center requires submission
of minimal essential data form from all consecutive patients to a
central registry. Since 1996, accredited EBMT centers are subject
to on-site audits. Since January 2003, all transplant centers have
been required to obtain written informed consent prior to data
registration following the Declaration of Helsinki 1975.
CIBMTR is a working group of .500 transplantation centers
worldwide that contribute detailed data on HCT to a statistical
center at the Medical College of Wisconsin. Participating centers
are required to report all transplantations consecutively; patients
are followed longitudinally, and compliance is monitored by on-site
audits. Computerized checks for discrepancies, physicians’ review
of submitted data, and on-site audits of participating centers ensure
data quality. The CIBMTR collects data at 2 levels: transplant
essential data in all patients and more comprehensive data in a
subset of patients selected by a weighted randomization scheme.
Observational studies conducted by the CIBMTR are performed
in compliance with all applicable federal regulations pertaining to
the protection of human research participants. Protected Health
Information used in the performance of such research is collected
and maintained in CIBMTR’s capacity as a Public Health Authority
under the Health Insurance Portability and Accountability Act of
1996 Privacy Rule. The institutional review boards of the Medical
College of Wisconsin and the National Marrow Donor Program
approved this study.
Study design
This was a collaborative retrospective registry-based analysis.
Eligible were adult ($18 years) patients with DLBCL who had
undergone their first nonmyeloablative or reduced-intensity condi-
tioning (NMC/RIC) allo-HCT between 2008 and 2015. Eligible do-
nors included MSD, 8/8 MUD (allele-level match at HLA-A, -B, -C,
and -DRB1), or haploidentical related donors (mismatched for $2
HLA loci). Recipients of haplo-HCT were limited to those receiving
GVHD prophylaxis with PTCy (with or without CNI and mycophe-
nolate mofetil). GVHD prophylaxis in MSD was limited to CNI-based
approaches without antithymocyte globulin/alemtuzumab in-vivo
T-cell depletion (TCD), while MUD recipients received CNI-based
prophylaxis with or without in vivo TCD. Patients receiving ex vivo
graft manipulation (eg, CD34 selection) were excluded. CIBMTR
cohort was limited to patients from the United States and Canada
only to avoid duplicate inclusion of European patients reported to
both registries.
Definitions
The intensity of allo-HCT conditioning regimens was categorized as
NMC/RIC using consensus criteria.24 Disease response at the time
of HCT was determined using the International Working Group
criteria in use during the era of this analysis.25
Study end points
The primary end point was overall survival (OS); death from any cause
was considered an event, and surviving patients were censored at
last follow-up. Secondary outcomes included nonrelapse mortality
(NRM), progression/relapse, and progression-free survival (PFS).
NRM was defined as death without evidence of prior lymphoma
progression/relapse; relapse was considered a competing risk.
Progression/relapse was defined as progressive lymphoma after
HCT or lymphoma recurrence after a complete response (CR);
NRM was considered a competing risk. For PFS, a patient was
considered a treatment failure at the time of progression/relapse
or death from any cause. Patients alive without evidence of disease
relapse or progression were censored at last follow-up. Acute
GVHD and chronic GVHD were graded using established clinical
criteria.26,27 GVHD-free, relapse-free survival (GRFS) was calcu-
lated using the modification proposed by Ruggeri et al for registry-
based studies.28 Probabilities of GRFS, PFS, and OS were calculated
using the Kaplan-Meier estimates. Neutrophil recovery was defined
as the first of 3 successive days with absolute neutrophil count
$0.5 3 109/L after posttransplantation nadir. Platelet recovery was
considered to have occurred on the first of 3 consecutive days
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with platelet count 203 109/L or higher in the absence of platelet
transfusion for 7 consecutive days. For neutrophil and platelet
recovery, death without the event was considered a competing risk.
Statistical analysis
The haplo-HCT cohort was compared against the MSD, MUD with
TCD (MUD TCD1), and MUD without TCD (MUD TCD2) cohorts.
Patient-, disease- and transplant-related variables were compared
among the 4 cohorts using the x2 test for categorical variables and
the Wilcoxon 2-sample test for continuous variables. Cumulative
incidences of hematopoietic recovery, acute and chronic GVHD,
relapse, and NRM were calculated to accommodate for competing
risks. Associations among patient-, disease-, and transplant-related
variables and outcomes of interest were evaluated using Cox
proportional hazards regression for chronic GVHD, relapse, NRM,
PFS, and OS and logistic regression for acute GVHD. Forward
stepwise selection was used to identify covariates that influenced
outcomes. Covariates with a P , .05 were considered significant.
The proportional hazards assumption for Cox regression was tested
by adding a time-dependent covariate for each risk factor and each
outcome. Covariates violating the proportional hazards assumption
were added as time-dependent covariates in the Cox regression
model. Interactions between the main effect and significant covariates
were examined. Results are expressed as odds ratio for acute
GVHD and relative risk (RR) for chronic GVHD, relapse, NRM,
PFS, and OS. The variables considered in multivariate analysis
are shown in supplemental Table 1. All statistical analyses were
performed using SAS version 9.4 (SAS Institute, Cary, NC).
Results
Patient and transplant characteristics
Altogether, 1438 eligible patients (haplo, 132; MSD, 525; MUD
TCD1, 403; and MUD TCD2, 378) were included. Compared with
the MSD and MUD cohorts, patients with haploidentical donors
were significantly older, had a better performance status (PS), and
were less likely to have received a prior auto-HCT. Moreover, total
body irradiation (TBI)–based conditioning and bone marrow grafts
as standard elements of the original PTCy platformwere predominantly
used in the haplo-HCT group, while the vast majority of the MSD/
MUD transplants were performed with peripheral blood grafts
and TBI-free conditioning. In contrast, there were no significant
differences in terms of sex, time from diagnosis to transplant, and
disease status at HCT among the 4 cohorts. Details are given in
Table 1.
Hematopoietic recovery
Although the proportion of patients having achieved neutrophil
recovery by day 128 tended to be lower in the haplo group (90%)
than in the MSD/MUD cohorts (95% to 97%), this difference was
not statistically significant. Virtually all patients in all groups had
reached neutrophil engraftment by day 1100. In contrast, platelet
recovery was significantly delayed in the haplo group, with 61%
and 91% by day 128 and day1100, respectively, compared with
89% to 92% and 96% to 98%, respectively, in the MSD/MUD
cohorts (Table 2).
GVDH
Acute GVHD grade 2 to 4 (grade 3 to 4) was reported in 34% (7%)
of the haplo-transplanted patients and was thus not significantly
different from the acute GVHD rates in the MSD group (32% [11%])
and the MUD TCD1 group (32% [13%]). In contrast, the grade
2 to 4 (42%) and grade 3 to 4 (19%) acute GVHD risk was signif-
icantly increased in patients transplanted from MUD without TCD
in univariate and multivariate comparisons (Tables 2 and 3). The
cumulative incidence of chronic GVHD at 1 and 2 years after
haplo-HCT was 15% and 18%, respectively. This was significantly
lower than the corresponding incidences in the MSD group (41%
and 48%), the MUD TCD1 group (23% and 27%), and the MUD
TCD2 group (48% and 57%) by univariate and multivariate compar-
isons (Tables 2 and 3; Figure 1A). Within the MUD TCD1 cohort,
compared with ATG, the use of alemtuzumab was associated with
a significant reduction of grade 3 to 4 acute GVHD but did not
affect any other end point (supplemental Table 3).
NRM
The 3-year cumulative incidences of NRM in the haplo-HCT, MSD,
MUD TCD1, and MUD TCD2 cohorts were 22%, 17%, 26%, and
30%, respectively (Table 2; Figure 1B). There was no significant
difference among the 4 groups on multivariate analysis if the haplo-
HCT cohort was used as reference. However, the MSD cohort had
a significantly reduced NRM risk if the MUD TCD2 cohort served as
comparator (RR, 0.71; 95% confidence interval [CI)], 0.54-0.93;
P 5 .01) (Table 3). Other significant predictors of NRM risk were
increasing age and HCT-CI (supplemental Table 4).
Disease control
The 3-year cumulative incidence of relapse/progression was 41%
(95% CI, 32% to 49%) in the haplo-HCT group compared with the
3-year cumulative incidence of 47%, 38%, and 34% for the MSD,
MUD TCD1, and MUD TCD2 cohorts, respectively. On multivar-
iate analysis, the relapse incidence tended to be lower with MUD
TCD2 than with haplo-HCT (RR, 0.73; 95% CI, 0.53-1.00; P 5
.05). Compared with MUD TCD2, MSD-HCT was associated with
a higher risk of relapse/progression (RR, 1.45; 95% CI, 1.17-1.80;
P 5 .0008) (Tables 2 and 3). Other factors adversely affecting
relapse risk are shown in supplemental Table 4. Of note, the majority
of relapse/progression events occurred during the first posttrans-
plant year in all 4 donor groups (Figure 1C).
Survival
With a median follow-up of 4.1 (1.0-6.1) years, 3-year OS in the
haplo-HCT group was 46% (95% CI, 37% to 55%) and thus
comparable to the matched donor groups, with 50%, 43%, and
46% for MSD, MUD TCD1, and MUD TCD2, respectively
(Table 2; Figure 1E). Similarly, there were no significant differences
in PFS (38%, 37%, 36%, and 37% at 3 years for haplo donors,
MSD, MUD TCD1, and MUD TCD2, respectively) (Table 2;
Figure 1D). Multivariate analyses confirmed the absence of signif-
icant OS and PFS differences among the 4 groups (Table 3).
In contrast, disease status less than CR and decreased PS
significantly reducedOS and PFS onmultivariate analysis. In addition,
OS was affected by increasing age and HCT-CI (supplemental
Table 4).
Two-year composite end point GRFS following haplo-HCT was
36% (95% CI, 28% to 45%) compared with 23% (95%CI 19% to
27%) following MSD (P 5 .007), 19% (95% CI, 15% to 24%)
following MUD TCD2 (P , .001) and 33 (95% CI, 28% to 39%)
following MUD TCD1 (P5 .60) (Figure 1F). However, when GRFS
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Table 1. Patient characteristics
Haplo donor MSD MUD TCD1 MUD TCD2 P
Number of patients 132 525 403 378
Number of centers 24 86 45 51
Reporting registry ,.001
CIBMTR 97 (73) 353 (67) 166 (41) 263 (70)
EBMT 35 (27) 172 (33) 237 (59) 115 (30)
Patient age, median (range), y 58 (20-75) 55 (19-73) 55 (19-75) 56 (23-73) ,.001
Patients $60 y 59 (45) 135 (26) 121 (30) 134 (35)
Male sex 86 (65) 323 (62) 259 (64) 218 (58) .22
KPS $90 96 (73) 325 (62) 249 (62) 216 (57) .003
KPS missing 5 (4) 24 (4) 26 (6) 10 (2)
HCT-CI ,.001
0 33 (25) 119 (23) 54 (13) 63 (17)
1-2 31 (23) 112 (21) 75 (19) 84 (22)
$3 36 (27) 137 (26) 85 (21) 125 (33)
Missing* 33 (25) 157 (30) 189 (47) 106 (28)
Patient race ,.001
White 91 (69) 349 (66) 258 (64) 282 (75)
African American 15 (11) 12 (2) 2 (,1) 5 (1)
Other 2 (2) 36 (8) 2 (,1) 7 (1)
Missing 24 (18) 128 (24) 141 (36) 84 (22)
Time from diagnosis to transplant,
median (range), mo
22 (,1-173) 26 (2-386) 24 (2-340) 28 (2-299) .18
Previous auto-HCT 56 (42) 288 (55) 237 (59) 229 (61) .002
Remission status at HCT .72
Complete 63 (48) 217 (41) 179 (44) 171 (45)
Partial 45 (34) 181 (34) 133 (33) 133 (35)
Refractory 23 (17) 109 (21) 74 (18) 64 (17)
Untreated/unknown 1 (,1) 18 (4) 17 (5) 10 (3)
TBI in conditioning† 114 (86) 109 (21) 30 (7) 121 (32) ,.001
Graft type ,.001
Bone marrow 100 (76) 10 (2) 30 (7) 20 (5)
Peripheral blood 32 (24) 515 (98) 373 (93) 358 (95)
CMV status
D1/R2 11 (8) 38 (7) 21 (5) 31 (8) ,.001
Missing 64 (49) 257 (49) 240 (58) 120 (31)
D-R sex match ,.001
Female-male 42 (32) 139 (26) 95 (24) 66 (17)
Other 90 (68) 386 (74) 306 (75) 311 (82)
Missing 0 2 (,1) 2 (,1) 1 (,1)
GVHD prophylaxis ,.001
PTCy 132 N/A N/A N/A
CNI 1 MMF 6 others N/A 191 (36) 158 (39) 159 (42)
CNI 1 MTX 6 others N/A 236 (45) 154 (38) 150 (40)
CNI 1 others N/A 98 (19) 91 (23) 69 (18)
Follow-up of survivors, median (range), mo 49 (12-73) 48 (2-97) 49 (3-100) 39 (4-96)
Values in parentheses represent percentages if not indicated otherwise.
A/C, anti–thymocyte globulin/alemtuzumab; CMV, cytomegalovirus; D-R, donor-recipient; HCT-CI, hematopoietic cell transplant-comorbidity index; KPS, Karnofsky performance score;
MMF, mycophenolate mofetil; MTX, methotrexate; N/A, not applicable; w, with; w/o, without.
*EBMT does not collect this variable for minimal essential data (MED-A) patients.
†Details of conditioning regimens are given in supplemental Table 2.
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of the haplo group was broken down to graft source, it seemed
that the benefit was restricted to those patients who received
a marrow graft (2-year GRFS 40% (95% CI, 30% to 50%) for
bone marrow vs 23% (95% CI, 8% to 41%) for peripheral blood;
P 5 .08).
To ensure that outcomes reported in the current analysis were
not driven by institutional expertise, transplant center effect was
examined using the random effect score test. No center effect on
the hazard of OS (P5 .71), PFS (P5 .89), relapse (P5 .43), and
NRM (P 5 .50) was seen.
Causes of death
The most common cause of death in all 4 cohorts was progressive
DLBCL (haplo, 44%; MSD, 53%; MUD TCD1, 47%; and MUD
TCD2, 34%). GVHD was considered as main cause of death only
in minority of patients, with the highest proportion in the MUD
TCD2 group (11%), followed by MUD TCD1 (6%) and MSD and
haplo-HCT (3% each) (supplemental Table 5).
Discussion
Allo-HCT is an effective treatment strategy to rescue patients with
DLBCL who relapse after auto-HCT and as a first transplant in
those patients with adverse prognostic features at the time
of relapse that predict poor outcomes with auto-HCT.5 The
availability of haplo donors in this setting would eventually give
almost every transplant-eligible patient access to allo-HCT. The
joint analysis performed by the EBMT and CIBMTR presented
here indicates that with the precise inclusion criteria consid-
ered here, outcomes of haplo-HCT do not seem inferior to that
of standard donor sources (MSD and MUD). Of note, the cumu-
lative incidence of chronic GVHD after transplant was signifi-
cantly lower in the haplo group compared with MSD and MUD
TCD2, thus significantly improving GFRS after haplo-HCT in
comparison with T-replete transplantation from matched donors
(despite no differences in severe acute GVHD, relapse, and
mortality).
Similar to previous retrospective analyses of unspecified pooled
lymphoma populations,8-12 this first DLBCL-specific study on
haplo-HCT shows that all main survival outcomes are comparable
with those of standard well-matched donor transplants. This is
particularly noteworthy for the risk of relapse/progression, since
DLBCL appears to be less graft-versus-leukemia (GVL) sensitive
than other NHL entities, such as follicular lymphoma and mantle cell
lymphoma,23,29 and thusmight rely more on intensive conditioning.10
Table 2. Univariate outcomes
Outcomes
Haploidentical donor (n5 132) MSD (n 5 525) MUD TCD1 (n 5 403) MUD TCD2 (n 5 378)
Eval Prob (95% CI), % Eval Prob (95% CI), % Eval Prob (95% CI), % Eval Prob (95% CI), % P
Neutrophil recovery 126 475 383 336 .004
28 d 90 (84-94) 97 (95-98)* 95 (93-97) 96 (93-98) .10
100 d 99 (97-100) 99 (98-100) 98 (97-99) 99 (98-100) .79
Platelet recovery 82 342 276 238 ,.001
28 d 61 (50-71) 92 (89-95)* 89 (85-92)* 89 (84-92)* ,.001
100 d 91 (84-96) 99 (97-100)* 96 (93-98) 98 (96-99) .01
Acute GVHD 2-4 123 490 377 359 .001
180 d 34 (26-43) 32 (28-36) 32 (28-38) 42 (37-47) .01
Acute GVHD 3-4 123 456 377 359 ,.001
180 d 7 (3-12) 11 (9-14) 13 (10-16) 19 (15-23)* ,.001
Chronic GVHD 124 522 403 335 ,.001
1 y 15 (9-21) 41 (37-46)* 23 (19-28) 48 (42-53)* ,.001
2 y 18 (12-26) 48 (43-52)* 27 (23-32) 57 (52-63)* ,.001
NRM 132 525 403 378 .001
1 y 16 (10-23) 13 (10-16) 21 (17-26) 20 (16-24) .007
3 y 22 (15-30) 17 (13-20) 26 (21-31) 30 (25-35) ,.001
Relapse/progression 132 525 403 378 ,.001
1 y 34 (26-43) 39 (34-43) 33 (28-38) 28 (23-33) .01
3 y 41 (32-49) 47 (42-51) 38 (33-43) 34 (29-39) .001
PFS 132 525 403 378 .72
1 y 50 (41-58) 48 (44-53)% 46 (40-51) 52 (47-57) .32
3 y 38 (29-47) 37 (32-41) 36 (31-41) 37 (31-42) .99
OS 132 525 403 378 .36
1 y 66 (58-74) 65 (61-69) 56 (51-61) 63 (58-68) .03
3 y 46 (37-55) 50 (45-55) 43 (38-49) 46 (41-52) .32
Eval, number of evaluable patients; Prob, probability; TCD1, TCD with alemtuzumab or anti–thymocyte globulin; TCD2, TCD without alemtuzumab or anti–thymocyte globulin.
*Significant pairwise comparisons in reference to the haploidentical donor group.
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The fact that the vast majority of the haplo transplants in this study
were performed using the nonmyeloablative Baltimore conditioning
regimen (67%; supplemental Table 2) providing only modest
antilymphoma activity implies that the GVL effect conferred with the
bone marrow/PTCy haplo platform is potent enough to compensate
for an eventually reduced contribution of the conditioning regimen
to disease control. Of note, this seems to be the case despite a
strongly reduced incidence of chronic GVHD, as it is the rule in
PTCy-based haplotransplants.
However, unlike in indolent B-cell neoplasms,23,30 the association
between chronic GVHD and GVL is less well documented in
DLBCL allotransplants.8-10,23 Accordingly, the reduced incidence
Table 3. Multivariate analysis
n OR or RR* Lower CL Upper CL P Overall P
Acute grade 2-4 GVHD
Haploidentical donors 123 1 .009
MSD 493 0.88 0.58 1.33 .54
MUD TCD1 377 0.92 0.60 1.41 .70
MUD TCD2 359 1.39 0.90 2.13 .13
Acute grade 3-4 GVHD
Haploidentical donors 123 1 .0007
MSD 493 1.56 0.75 3.26 .24
MUD TCD1 377 1.84 0.88 3.89 .11
MUD TCD2 359 3.05 1.47 6.32 .0028
Chronic GVHD
Haploidentical donors 127 1 ,.0001
MSD 469 3.15 2.08 4.77 ,.0001
MUD TCD1 321 2.05 1.32 3.17 .001
MUD TCD2 344 4.06 2.68 6.15 ,.0001
NRM
Haploidentical donors 132 1 .08
MSD 522 0.90 0.60 1.36 0.62
MUD TCD1 403 1.17 0.77 1.76 0.46
MUD TCD2 378 1.28 0.86 1.91 0.23
Significant contrast
MSD vs MUD TCD2 0.71 0.54 0.93 .01
Relapse/progression
Haploidentical donors 132 1 .009
MSD 525 1.06 0.79 1.41 .71
MUD TCD1 403 0.92 0.68 1.25 .60
MUD TCD2 378 0.73 0.53 1.00 .05
Significant contrast
MSD vs MUD TCD2 1.45 1.17 1.80 .0008
PFS
Haploidentical donors 132 1 .45
MSD 522 0.94 0.74 1.19 .61
MUD TCD1 403 0.97 0.76 1.24 .84
MUD TCD2 378 0.86 0.67 1.09 .21
OS
Haploidentical donors 132 1 .52
MSD 522 0.90 0.69 1.16 .42
MUD TCD1 403 1.02 0.78 1.33 .90
MUD TCD2 378 0.91 0.70 1.19 .49
The main effect of multivariate analysis is shown. Complete multivariate analysis results are provided in supplemental Table 3.
CL, confidence limit.
*Values are odds ratios (ORs) for “Acute grade 2-4 GVHD” and “Acute grade 3-4 GVHD”; all others are RR.
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of chronic GVHD observed in our haplo group did not signifi-
cantly increase the risk of relapse/progression, suggesting that
the composite end point GRFS seems to be clinically relevant
in patients with DLBCL. To this end, haplo-HCT with the PTCy
platform may have advantages over CNI-based matched donor
transplants in this entity, although the subset analyses of our haplo
cohort suggest that the superior GRFS observed may be due to the
use of bone marrow instead of peripheral blood grafts (which were
used in the vast majority of the patients in the matched donor
groups).31,32 In contrast, the delayed platelet engraftment associ-
ated with haplo-HCT, as shown in this and other studies,21 may
have adverse implications in terms of quality of life and resource
utilization, but a detailed analysis of this issue was beyond the scope
of our study.
When interpreting the results of the present analysis, some important
shortcomings inherent to the design of the study need to be taken
into consideration. There are some significant differences in terms of
clinical characteristics before transplant between haplo patients and
patients in other groups, such as PS and rate of prior auto-HCT,
which may have confounded the comparison despite Cox modeling
(supplemental Tables 1 and 4). Moreover, and as expected, the
transplant procedure was also different between the haplo group and
the other groups; more TBI-based conditioning regimens were used
in the haplo patients, and bone marrow cells were more frequently
used. Most importantly, and by definition, GVHD prophylaxis was
inherently different among groups. As results of allo-HCT using the
PTCy bone marrow platform in HLA-compatible settings emerge,33,34
it will be important to study how PTCy-based matched donor
transplants compare with PTCy-based haplo-HCT in DLBCL.
Currently, the use of PTCy in matched donor HCT remains
uncommon; for example, from 2015 to 2016, only ;8% (n 5 19)
of DLBCL patients undergoing MSD or MUD HCT in the United
States received PTCy-based GVHD prophylaxis. Data on genetic
risk factors (such as c-myc status) are not routinely collected by
the CIBMTR and EBMT registries and may have differed between
groups. Finally, additional confounders that could not be compen-
sated in the present analysis, such as center effects, may have
biased the comparisons performed here.
Of note, myeloablative conditioning regimens were disregarded
in this analysis. The major reason for that was to reduce the
MUD with ATG/alemtuzumabHLA identical sibling
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Figure 1. Transplantation outcomes. (A) Cumulative incidence of chronic GVHD. (B) Cumulative incidence of NRM. (C) Cumulative incidence of relapse. (D) PFS. (E) OS.
(F) GRFS. ATG, anti–thymocyte globulin.
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heterogeneity in the groups, as the number of patients identified
in the 2 registries who were transplanted using a myeloablative
conditioning regimen was ,20 in the haplo group. NMC/RIC
allotransplants represent a significant proportion of this activity
in patients with DLBCL; allo-HCT is most frequently used when
patients fail auto-HCT, and information coming from some
registry analyses indicates that the intensity of the condition-
ing regimen does not significantly modify the outcome of the
procedure.35,36
With more than 1400 patients, this study is also the largest
ever performed on allo-HCT for DLBCL, and survival data are
in keeping with those observed in previous smaller series inves-
tigating both MSD and MUD transplants.8-10,12,37 Moreover, the
present study confirms for the first time for DLBCL earlier findings
made in MUD transplants in patients with acute leukemia38
and unspecified lymphoma19 suggesting that in vivo TCD with
ATG does not improve NRM and overall mortality despite a
reduced incidence of chronic GVHD (although the latter effect
was not significant in the present study). This is in contrast
with the only prospective study on allo-HCT in DLBCL performed
to date.10
In the era of novel treatment strategies, one must take into con-
sideration the potential impact that CAR-T cells will have on the
use of allogeneic strategies. The pivotal phase 2 clinical trial
ZUMA-14 using axicabtagene ciloleucel, an anti-CD19 CAR-T-cell
construct, in patients with relapsed/refractory DLBCL initially dem-
onstrated a durable CR rate in 40% of the patients with a median
follow-up of 15.4 months. Comparable results were observed in
phase 2 trials using tisagenlecleucel and lisocabtagene mar-
aleucel, respectively, in patients with multiply relapsed/refractory
aggressive B-cell lymphoma, although the follow-up was still
short.39,40 Treatment-related toxicity mainly included neurological
effects and cytokine release syndrome, but the NRM associated
with CD19 CAR-T cells in DLBCL seems to be generally ,5%.
Although these compelling results will potentially compete with
those of allo-HCT, the number of patients treated with CAR-T cells
is still quite limited, and follow-up is too short to be meaningful for
long-term outcome. For example, in the long-term follow-up of
ZUMA-1 subjects, while median OS was not reached, the median
PFS was a modest 5.9 months.41 Finally, the enormous economic
impact associated with this treatment strategy has to be taken into
account. The currently ongoing global phase 3 trials comparing
CAR-T cells with standard of care in second-line treatment will
help to define the role of CAR-T cells in the treatment algorithm
of DLBCL.
The transplant registry character of the current study precludes
conclusions on the impact of allo-HCT on the natural history
of DLBCL. For example, only a minority of those patients who
had DLBCL recurrence after auto-HCT on the CORAL trial were
able to proceed to salvage allo-HCT.42 Future studies should
therefore follow an intent-to-treat design, ideally comparing allo-
HCT with CAR-T-cell therapies in a prospective randomized
manner.
In summary, this study suggests that in DLBCL outcome after
RIC haplo-HCT with PTCy may be comparable to that after RIC
allo-HCT using matched donors despite a lower risk of chronic
GVHD, at least if marrow is used as a haplo graft source. This
might be of particular relevance in patients with highly proliferative
or advanced disease who need to rapidly proceed to an allo-HCT.
However, additional studies are needed before haploidentical
donors can be considered as equivalent to well-matched related
or unrelated donors in patients with DLBCL.
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